Incyte Corporation (BVMF:I1NC34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 96.59B +41.3% |
| Revenue (ttm) | 27.97B +21.5% |
| Net Income | 7.47B +6,631.4% |
| EPS | 36.82 +7,175.4% |
| Shares Out | n/a |
| PE Ratio | 12.93 |
| Forward PE | 11.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 80 |
| Open | 240.72 |
| Previous Close | 238.88 |
| Day's Range | 240.72 - 240.72 |
| 52-Week Range | 185.15 - 299.88 |
| Beta | n/a |
| RSI | 42.81 |
| Earnings Date | Apr 28, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Inside Incyte's $120 Million AI For Drug Development Deal
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.
Incyte, Genesis Molecular AI announce expansion of collaboration
Incyte (INCY) and Genesis Molecular AI announced a significant expansion of their strategic collaboration building and deploying AI to accelerate the discovery of novel molecules for collaboration tar...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collaboration to accelerate drug discovery.
Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026
Phase III for mutant CALR antibody 989 in ET starts mid-year with a novel, user-friendly design and rapid endpoints. MF program pursues composite endpoints, while subQ formulations and next-gen assets advance. Jakafi XR, tafasitamab, and povo are positioned for significant market growth.
Incyte, Edison Scientific announce strategic collaboration to employ Kosmos
Incyte (INCY) and Edison Scientific announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. Kosmos will be embedded across the Incyte ...
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
WILMINGTON, Del. & SAN FRANCISCO--(BUSINESS WIRE)---- $INCY--Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development.
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Incyte NASDAQ: INCY President and CEO Bill Meury said the company's post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business, la...
Incyte Transcript: Bank of America Global Healthcare Conference 2026
Leadership highlighted a year of transformation, robust financials, and a clear post-2029 growth strategy. Key products Jakafi and OPZELURA are driving near-term growth, while pipeline assets like MONJUVI, POVO, and mCALR are positioned to sustain momentum. International expansion and strategic business development are central to future plans.
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2026--Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress.
Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
Incyte (INCY) announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura cream in adults with moderate atopic dermatitis who had an inadequate…
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte gets orphan designation for treatment of pancreatic cancer
Incyte (INCY) Corporation was granted FDA orphan designation for a treatment of pancreatic cancer, according to a post to the agency’s website.
Incyte announces FDA approval of Jakari XR
Incyte (INCY) announced that the U.S. Food and Drug Administration has approved Jakafi XR extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis; adults wit...
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatmen...
Incyte price target raised to $90 from $84 at Oppenheimer
Oppenheimer raised the firm’s price target on Incyte (INCY) to $90 from $84 and keeps a Perform rating on the shares. The firm notes the company reported Q1 results boasting…
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences.
Incyte price target raised to $123 from $120 at Stifel
Stifel raised the firm’s price target on Incyte (INCY) to $123 from $120 and keeps a Buy rating on the shares.
Incyte price target raised to $124 from $121 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $124 from $121 and keeps a Buy rating on the shares. The Q1 report showed typical seasonality, but FY26 guidance…
Incyte beats first-quarter estimates on strong demand for cancer drugs
Drugmaker Incyte beat analysts' estimates for first-quarter profit and revenue on Tuesday, partly helped by strong demand for its cancer treatments, including Jakafi and Minjuvi.
Incyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% net sales growth and strong performance across all segments, with robust pipeline progress and new leadership appointments. Full-year guidance was reaffirmed, and multiple late-stage regulatory and clinical milestones were achieved.
Incyte Earnings release: Q1 2026
Incyte released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Incyte Slides: Q1 2026
Incyte has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Incyte Quarterly report: Q1 2026
Incyte has published its Q1 2026 quarterly earnings report on April 28, 2026.
Incyte Proxy statement: Proxy filing
Incyte filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.